Navigation Links
EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
Date:6/11/2008

Patent Covers Compositions and Methods

ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2- methoxyestradiol (2ME2). The patent grants EntreMed composition-of-matter and method of use intellectual property protection through 2025 for analogs of 2ME2 in oncology and a broad range of non-oncology indications, including inflammatory and immune disorders, rheumatoid arthritis, and other diseases characterized by abnormal cell division (mitosis).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Analogs of 2ME2 have been developed by EntreMed to improve metabolic stability and retain or enhance antiproliferative and antiangiogenic properties. Preclinical results demonstrate that certain analogs of 2ME2 can attack tumors on multiple fronts -- directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells, through inhibition of mitosis and induction of apoptosis, and by blocking blood vessels that feed tumors (angiogenesis inhibition).

U.S. Patent No. 7,371,741 entitled "Estradiol derivatives and pharmaceutical compositions using same," covers analogs that have been modified at certain positions on the 2-methoxyestradiol structure, yet retain their ability to inhibit cell proliferation. In addition, the '741 patent claims methods for treating tumors with compounds having the claimed structural modifications of 2-methoxyestradiol. The '741 patent covering the issued claims is owned exclusively by EntreMed.

James S. Burns, EntreMed President & Chief Executive Officer, commented, "This patent is the result of an extensive internal program to identify novel compounds based on our expertise in angiogenesis, cell cycle regulation and cell signaling. This patent further strengthens our intellectual property position in next generation antimitotic and antiangiogenic drugs for the treatment of cancer. ENMD-1198, a lead compound resulting from our analog program, is currently in a Phase 1 study in advanced cancers. We anticipate completion of the study in the second half of 2008. Additional studies, including an expanded Phase 1 or Phase 2 trial, are planned for later this year."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... , Jan 20, 2017 Research and Markets ... Analysis & Trends - Technology, Route Of Administration, End User - ... ... is poised to grow at a CAGR of around 7.8% over ... This industry report analyzes the global markets for Advanced ...
(Date:1/20/2017)... 2017  Ethicon Endo-Surgery, Inc. announced today ... Inc., a privately held medical device company ... used in operating rooms worldwide. The acquisition ... energy devices with Megadyne,s innovative portfolio of ... in Ethicon,s goal to deliver the most ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica ... Travis-Teague, the electrifying line-up of events for its annual meeting “Coming Home 2017,” ... community. “Coming Home 2017” will be held on Friday January 27 through ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million women ... of recovery, they often feel shame for having struggled with an eating disorder as ... the workshop, “Rising Strong in Life After an Eating Disorder” -- to be featured ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... A new ... donate items they no longer use or need, from clothes to couches to dressers ... unwanted items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... ... ... Doctor C LLC, a company based out of Arizona that focuses on ... marketing and distribution of its product, The Right C. , The Right C is ... traditional vitamin C supplements. At the trade show, Doctor C had the opportunity to ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an ... lives, recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting ... its large range of supplements that keep the body functioning at its peak ...
Breaking Medicine News(10 mins):